Calyxha Biotechnologies announces grant of a European Patent on neurodegenerative diseases

Austrian biotech company Calyxha Biotechnologies GmbH announced the grant of European Patent No. EP3383381.

This patent covers the use of calixarene compounds for neurodegenerative diseases, including Parkinson’s disease. It represents the company’s first granted patent, with prosecution of the corresponding patent applications ongoing in other territories.

Read more